Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma

Leukemia and Lymphoma

Volumn 57, Issue 7, 2016, Pages 1546-1559

  Moreau, Philippe ^a   Facon, Thierry ^b   Touzeau, Cyrille ^a   Benboubker, Lotfi ^c   Delain, Martine ^c   Badamo Dotzis, Julie ^d   Phelps, Charles ^e   Doty, Christopher ^f   Smit, Hans ^f   Fourneau, Nele ^f   Forslund, Ann ^f   Hellemans, Peter ^f   Leleu, Xavier ^b  

^a HÔTEL DIEU   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CHU BRETONNEAU   (France)

^d IQVIA   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Bortezomib; dexamethasone; histone deacetylase inhibitor; multiple myeloma; quisinostat

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; DEXAMETHASONE; QUISINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; ATRIAL FIBRILLATION; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DYSPNEA; EDEMA; ERYTHEMA; ERYTHEMA MULTIFORME; FEMALE; HEART ARREST; HEART DISEASE; HEART VENTRICLE FIBRILLATION; HERPES ZOSTER; HUMAN; HUMAN CELL; HYPOTENSION; INSOMNIA; LUNG DISEASE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE SPASM; MYELOMA CELL; NAUSEA; NEURALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SENSORY NEUROPATHY; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; DRUG MONITORING; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE; RETREATMENT; TREATMENT OUTCOME; TUMOR EMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; BORTEZOMIB; DEXAMETHASONE; DRUG MONITORING; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NEOPLASTIC CELLS, CIRCULATING; RECURRENCE; RETREATMENT; TREATMENT OUTCOME;

EID: 84954200475     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1117611     Document Type: Article

References (37)

1. S.Bringhen, M.V.Mateos, S.Zweegman,. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;6:980–987.
2. M.Gupta, P.Rana Arun Gopal Krishan, D.Tikoo Multiple myeloma: the disease and its treatment. Int J Basic Clin Pharmacol. 2013;2:103–121.
3. Z.Zeng, J.Lin, J.Chen Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Ann Hematol. 2013;7:935–943.
4. P.M.Fayers, A.Palumbo, C.Hulin,. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2013;5:1239–1247.
5. M.V.Mateos, A.Oriol, J.Martínez-López,. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;10:934–941.
6. M.V.Mateos, P.G.Richardson, R.Schlag,. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;13:2259–2266.
7. J.F.San Miguel, R.Schlag, N.K.Khuageva,. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;9:906–917.
8. X.He, K.Yang, P.Chen,. Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. Onco Targets Ther. 2014;7:1593–1599.
9. D.C.Drummond, C.O.Noble, D.B.Kirpotin,. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005;45:495–528.
10. M.S.Kim, H.J.Kwon, Y.M.Lee,. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001;4:437–443.
11. P.Marks, R.A.Rifkind, V.M.Richon,. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;3:194–202.
12. C.Grant, F.Rahman, R.Piekarz,. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010;10:997–1008.
13. B.S.Mann, J.R.Johnson, M.H.Cohen,. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247–1252.
14. J.F.San-Miguel, V.T.Hungria, S.S.Yoon,. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;11:1195–1206.
15. J.Arts, P.King, A.Mariën,. JNJ-26481585, a novel “second-generation” oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009; 22:6841–6851.
16. S.Deleu, M.Lemaire, J.Arts,. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia. 2009;10:1894–1903.
17. T.Stühmer, J.Arts, M.Chatterjee,. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br J Haematol. 2010;4:529–536.
18. S.Deleu, M.Lemaire, J.Arts Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res. 2009;13:5307–5311.
19. T.Hideshima, J.E.Bradner, D.Chauhan,. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res. 2005;24:8530–8533.
20. A.Rodriguez-Gonzalez, T.Lin, A.K.Ikeda,. Role of the aggresome pathway in cancer targeting histone deacetylase 6-dependent protein degradation. Cancer Res. 2008;8:2557–2560.
21. S.Fotheringham, M.T.Epping, L.Stimson,. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell. 2009;1:57–66.
22. K.Ito, P.J.Barnes, I.M.Adcock Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 2000;18:6891–6903.
23. B.Venugopal, R.Baird, R.S.Kristeleit,. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res. 2013;15:4262–4272.
24. A.J.Yarnall, D.P.Breen, G.W.Duncan,. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 2014;4:308–316.
25. A.Palumbo, O.Sezer, R.Kyle,. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;10:1716–1730.
26. M.C.Miller, G.V.Doyle, L.W.Terstappen Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421. [Epub 2009 Dec 9]. DOI: 10.1155/2010/617421.
27. C.Le Tourneau, J.J.Lee, L.L.Siu Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;10:708–720.
28. K.Fizazi, F.Lesaunier, R.Delva,. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer. 2012;2:209–217.
29. P.G.Richardson, R.L.Schlossman, M.Alsina,. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;14:2331–2337.
30. M.Dimopoulos, D.S.Siegel, S.Lonial,. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013;11:1129–1140.
31. P.Moreau, H.Pylypenko, S.Grosicki Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;5:431–440.
32. R.Z.Orlowski, A.Nagler, P.Sonneveld,. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–3901.
33. P.G.Richardson, P.Sonneveld, M.W.Schuster,. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;24:2487–2498.
34. T.Hamaguchi, T.Ito, Y.Inoue,. Purification, characterization and molecular cloning of a novel endo-beta-N-acetylglucosaminidase from the basidiomycete, Flammulina velutipes. Glycobiology. 2010;20:420–432.
35. J.F.San-Miguel, P.G.Richardson, A.Günther,. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;29:3696–3703.
36. S.J.Harrison, H.Quach, E.Link,. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood. 2011;24:6274–6283.
37. A.Badros, A.M.Burger, S.Philip,. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res. 2009;16:5250–5257.